BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31194887)

  • 1. The risk of cytomegalovirus infection after treatment of acute rejection in renal transplant recipients.
    Jorgenson MR; Descourouez JL; Lyu B; Astor BC; Garg N; Smith JA; Mandelbrot DA
    Clin Transplant; 2019 Aug; 33(8):e13636. PubMed ID: 31194887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
    Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
    Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes.
    Jorgenson MR; Descourouez JL; Cardinale B; Lyu B; Astor BC; Garg N; Saddler CM; Smith JA; Mandelbrot DA
    Transpl Infect Dis; 2019 Jun; 21(3):e13080. PubMed ID: 30891915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N; Koutsokera A; Pasquier J; Mombelli M; Meylan P; Pascual M; Aubert JD; Manuel O
    Transpl Infect Dis; 2018 Aug; 20(4):e12893. PubMed ID: 29603543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.
    Werzowa J; Schwaiger B; Hecking M; Strassl R; Schmaldienst S; Böhmig GA; Genser B; Säemann MD
    Clin Transplant; 2015 Dec; 29(12):1230-8. PubMed ID: 26458731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.
    Erdbruegger U; Scheffner I; Mengel M; Schwarz A; Verhagen W; Haller H; Gwinner W
    Nephrol Dial Transplant; 2012 Jan; 27(1):435-43. PubMed ID: 21712490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Kremers WK; Cosio FG; Patel R; Razonable RR
    Clin Infect Dis; 2008 Mar; 46(6):840-6. PubMed ID: 18260785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
    Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in renal transplant recipients: one center's experience.
    Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
    Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
    Sund F; Tufveson G; Döhler B; Opelz G; Eriksson BM
    Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection and graft rejection in renal transplantation.
    Dickenmann MJ; Cathomas G; Steiger J; Mihatsch MJ; Thiel G; Tamm M
    Transplantation; 2001 Mar; 71(6):764-7. PubMed ID: 11330539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.